Departments of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
J Neurol. 2021 Sep;268(9):3086-3104. doi: 10.1007/s00415-020-10380-x. Epub 2021 Jan 13.
To systematically describe central (CNS) and peripheral (PNS) nervous system complications in hospitalized COVID-19 patients.
We conducted a prospective, consecutive, observational study of adult patients from a tertiary referral center with confirmed COVID-19. All patients were screened daily for neurological and neuropsychiatric symptoms during admission and discharge. Three-month follow-up data were collected using electronic health records. We classified complications as caused by SARS-CoV-2 neurotropism, immune-mediated or critical illness-related.
From April to September 2020, we enrolled 61 consecutively admitted COVID-19 patients, 35 (57%) of whom required intensive care (ICU) management for respiratory failure. Forty-one CNS/PNS complications were identified in 28 of 61 (45.9%) patients and were more frequent in ICU compared to non-ICU patients. The most common CNS complication was encephalopathy (n = 19, 31.1%), which was severe in 13 patients (GCS ≤ 12), including 8 with akinetic mutism. Length of ICU admission was independently associated with encephalopathy (OR = 1.22). Other CNS complications included ischemic stroke, a biopsy-proven acute necrotizing encephalitis, and transverse myelitis. The most common PNS complication was critical illness polyneuromyopathy (13.1%), with prolonged ICU stay as independent predictor (OR = 1.14). Treatment-related PNS complications included meralgia paresthetica. Of 41 complications in total, 3 were para/post-infectious, 34 were secondary to critical illness or other causes, and 4 remained unresolved. Cerebrospinal fluid was negative for SARS-CoV-2 RNA in all 5 patients investigated.
CNS and PNS complications were common in hospitalized COVID-19 patients, particularly in the ICU, and often attributable to critical illness. When COVID-19 was the primary cause for neurological disease, no signs of viral neurotropism were detected, but laboratory changes suggested autoimmune-mediated mechanisms.
系统描述住院 COVID-19 患者的中枢(CNS)和周围(PNS)神经系统并发症。
我们对一家三级转诊中心的成年 COVID-19 确诊患者进行了一项前瞻性、连续、观察性研究。所有患者在住院和出院期间每天都接受神经系统和神经精神症状的筛查。使用电子健康记录收集三个月的随访数据。我们将并发症分为 SARS-CoV-2 神经嗜性、免疫介导或与危重病相关的病因。
从 2020 年 4 月至 9 月,我们连续纳入了 61 名住院 COVID-19 患者,其中 35 名(57%)因呼吸衰竭需要重症监护(ICU)治疗。61 名患者中有 28 名(45.9%)出现 41 例 CNS/PNS 并发症,ICU 患者比非 ICU 患者更常见。最常见的 CNS 并发症是脑病(n=19,31.1%),其中 13 名患者(GCS≤12)为严重脑病,包括 8 名患者为无动性缄默症。ICU 入住时间与脑病独立相关(OR=1.22)。其他 CNS 并发症包括缺血性卒中、活检证实的急性坏死性脑炎和横贯性脊髓炎。最常见的 PNS 并发症是危重病性多发神经病(13.1%),ICU 停留时间延长是独立预测因素(OR=1.14)。治疗相关的 PNS 并发症包括股外侧皮神经炎。在总共 41 例并发症中,3 例为感染后/感染性,34 例为与危重病或其他原因相关,4 例仍未解决。所有 5 例接受检查的患者的脑脊液中均未检测到 SARS-CoV-2 RNA。
住院 COVID-19 患者中 CNS 和 PNS 并发症很常见,尤其是在 ICU 中,且通常与危重病相关。当 COVID-19 是神经疾病的主要原因时,未发现病毒神经嗜性的迹象,但实验室变化提示自身免疫介导的机制。